Saturday 17 October 2026
Export IBRX’s income statement to Excel — free account
ImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024. In the quarter to June 2026, revenue grew 93.9%, EPS fell 120.0%, free cash flow grew 13.4% and total debt rose 57.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
9.18
0.82
−8.20%
Follow IBRX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
55.48 | 55.87 | 16.08 | 28.21 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(138.34) | (104.51) | (25.88) | (33.79) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
60.90 | 61.40 | 22.40 | 36.99 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(35.92) | (29.40) | (8.32) | (9.55) | |
EV/FCF |
(35.05) | (28.96) | (8.22) | (9.40) | |
Quick Ratio |
5.35 | 6.24 | 4.62 | 5.07 | |
Current Ratio |
5.72 | 6.67 | 5.10 | 5.77 | |
Net Debt/EBITDA |
(7.48) | (4.44) | (3.85) | (4.70) | |
Debt/Assets |
123.21% | 104.91% | 95.06% | 96.50% | |
Debt/Equity |
(0.74) | (0.78) | (0.95) | (0.96) | |
Asset Turnover |
0.32 | 0.30 | 0.26 | 0.19 | |
Operating CF/Net income |
0.29 | 0.12 | 1.14 | 1.02 | |
Capex/Depreciation |
(0.59) | (0.62) | (0.23) | (0.19) | |
Interest Coverage |
(1.97) | (2.67) | (2.30) | (2.02) | |
Research and Development Expense of Revenue |
118.69% | 153.80% | 166.79% | 159.80% | |
Selling, General and Administrative Expense of Revenue |
101.14% | 103.54% | 101.16% | 113.17% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
16.62% | 18.48% | 22.84% | 27.69% | |
Graham Net Nets |
(0.13) | (0.13) | (0.38) | (0.31) | |
Graham Number |
4.66 | 4.02 | 2.15 | 2.23 | |
Earnings Yield |
(11.07%) | (11.08%) | (19.19%) | (16.26%) | |
Free Cash Flow Yield |
(3.13%) | (3.79%) | (16.95%) | (13.95%) | |
Revenue per Share |
0.05 | 0.04 | 0.04 | 0.03 | |
Operating CF per Share |
(0.06) | (0.07) | (0.08) | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.07) | (0.08) | (0.08) | (0.07) | |
Cash per Share |
0.34 | 0.37 | 0.26 | 0.27 | |
Shareholders Equity per Share |
(1.00) | (0.85) | (0.54) | (0.55) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.00) | (0.85) | (0.54) | (0.55) | |
Free Cash Flow |
(70.01) | (77.13) | (71.28) | (69.65) | |
Working Capital |
362.25 | 385.00 | 253.12 | 272.36 | |
Capital Expenditures |
(3.52) | (1.78) | (0.90) | (0.74) | |
Net Current Asset Value |
(1,235.28) | (1,062.81) | (686.60) | (712.90) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.07 | 0.04 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
37.80 | 30.15 | 22.47 | 18.10 | |
Average Payables |
9.71 | 12.35 | 6.85 | 7.86 | |
Average Inventory |
4.29 | 4.50 | 4.59 | 4.33 | |
Average Assets |
515.29 | 475.20 | 442.42 | 441.78 | |
Average Common Equity |
(807.79) | (729.80) | (493.85) | (633.79) |
Columns are period end dates